Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

Abstract Background Trastuzumab and multiagent chemotherapy have been the standard of care for the 20-30% of metastatic gastric and esophageal adenocarcinomas that overexpress HER2. Preclinical data show that trastuzumab requires a functional adaptive immune system for efficacy, suggesting synergy o...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Vol. 30; no. 7
Main Authors: Lee, Michael S, Chao, Joseph, Mulcahy, Mary F, Kasi, Pashtoon M, Alistar, Angela T, Mukherjee, Sarbajit, Akce, Mehmet, Moore, Dominic T, McRee, Autumn J, Somasundaram, Ashwin
Format: Journal Article
Language:English
Published: US Oxford University Press 01.07.2025
Subjects:
ISSN:1083-7159, 1549-490X, 1549-490X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first